spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Gerresheimer establishes small series production in the USA

Gerresheimer AG

Pilot production in series quality at the Peachtree City production plant: Development samples, clinical samples all the way to small series production in every project phase for the company’s American customers


Wackersdorf, March 18, 2022:
Pharma and medical technology specialist Gerresheimer has established small series production at its Technical Competence Center at its Peachtree City, Georgia location. Small quantities of products can now be manufactured under series conditions and in ISO class 8 cleanroom. During the development and approval of pharmaceutical products and medical devices, this kind of small series is regularly needed for clinical samples or stability batches.



Prior to series production, pharmaceutical products and medical devices run through an exhaustive approval process for which small numbers of units need to be produced repeatedly, for examples, as clinical samples, development samples or stability batches. In 2013, Gerresheimer opened its own small series production at its Technical Competence Center in Wackersdorf, Germany, to accomplish this task. The company is now continuing this success story, starting small series production at its Peachtree City production location to be able to offer American customers small series production locally.

Besides providing small volumes of product, small series production also enables Gerresheimer to optimize the production process in the pilot phase. All the expertise required for series production can be established, while processes can be developed and streamlined. The experience gained during mold making and automation can be harnessed to design series molds and series equipment.

Setup of small series production began at the Technical Competence Center at the Peachtree City location in 2020 with the conversion of an existing building as well as setup of an ISO class 8 cleanroom in accordance with DIN EN ISO 14644-1. Small series production then took up operation in 2021. “The equipment in small series production adapts to the project. We are currently producing an innovative product for ophthalmology, an innovative point-of-care test system and a combination product in accordance with the FDA definition,” explains Manfred Baumann (Global Executive VP Sales & Marketing, Administration & TCC, Gerresheimer Regensburg GmbH). Based on these projects, the equipment in small series production currently includes an injection molding machine with a clamping force of 120 tons that connects with handling systems and parts conveyors. Project-specific assembly and packaging units such as granulation, fill & seal plants as well as manual assembly stations, including ultrasonic welding systems, are also available. For quality assurance, small series production has its own fully equipped measurement laboratory with product-specific testing equipment with optical and tactile measuring machines and other testing equipment.
phone +49-(0)211/61 81-00
email info@gerresheimer.com
web www.gerresheimer.com
email Klaus-Bungert-Str. 4, 40468 Duesseldorf, Germany
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Lesaffre Acquires Recombia Biosciences, a Biotechnology Company Specialized in High-Throughput Genome Editing and Synthetic Biology

Lesaffre, a global key player in the field of fermentation for nearly 170 years, today announces the acquisition of Recombia Biosciences, a biotechnology company based in the San Francisco Bay Area and founded in 2019 based on technology licensed from Stanford University. This acquisition is the culmination of a strategic partnership initiated in 2020 to leverage Recombia Biosciences’ genome-editing technologies and accelerate the development of yeasts for sustainable production of fermented ingredients. The partnership marked Lesaffre’s entry into the world of Synthetic Biology, considered to be one of the largest biotechnology opportunities of this decade.
More info >>


White Papers

Advantages of Quantitative NMR for the Determination of Relative Response Factors

Novatia, LLC

Quantitative NMR (qNMR) is a technique that is being applied broadly and at an increasing rate in the field of pharmaceutical analysis (1). This white paper highlights the advantages of using qNMR to determine Relative Response Factors (RRFs) for pharmaceutical impurities detectable by HPLC. A single determination of RRFs using qNMR allows for simple and accurate quantitation of impurities which eliminates the need for preparation, qualification, and storage of reference standards. An example is presented here, which demonstrates quantitation of known impurities that have variable responses to UV-VIS detection, thereby providing a more accurate assessment of impurity levels than UV-VIS response alone.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement